Lixte Biotechnology Holdings Inc

0.0072 (1.04%)


Draw Mode:

Volume 29,860
Bid Price 0.64
Ask Price 0.65
News -
Day High 0.68


52 Week Range


Day Low 0.63915
Company Name Stock Ticker Symbol Market Type
Lixte Biotechnology Holdings Inc LIXT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0072 1.04% 0.70 17:00:18
Open Price Low Price High Price Close Price Prev Close
0.672 0.63915 0.68 0.6625 0.6928
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
130 29,860 $ 0.6594164 $ 19,690 - 0.432 - 2.70
Last Trade Time Type Quantity Stock Price Currency
18:24:34 1 $ 0.65 USD

Lixte Biotechnology Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 11.66M 16.66M 16.63M $ - $ - -0.08 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 928.61k -

more financials information »

Lixte Biotechnology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No LIXT Message Board. Create One! See More Posts on LIXT Message Board See More Message Board Posts

Historical LIXT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.67550.720.56110.6844282125,8590.02453.63%
1 Month0.570.720.5110.63859977,2110.1322.81%
3 Months0.79010.950.4720.689815578,051-0.0901-11.4%
6 Months0.772.700.4591.55697,716-0.07-9.09%
1 Year0.752.700.4321.46385,662-0.05-6.67%
3 Years3.857.190.4322.32915,750-3.15-81.82%
5 Years3.857.190.4322.32915,750-3.15-81.82%

Lixte Biotechnology Description

Lixte Biotech Holdings Inc is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company focuses on developing new treatments for human cancers for which therapies are urgently needed. It mainly designs drugs for which there are existing data suggesting any effect on altered pathways of the cancer cell and may be given safely to humans. The development program of the company includes drugs for the treatment of cancer, consisting of protein phosphatase inhibitors and histone deacetylase inhibitors.